Credit Suisse Increases Adamas Pharmaceuticals Price Target to $30.00 (ADMS)
Credit Suisse raised their target price on shares of Adamas Pharmaceuticals (NASDAQ:ADMS) from $26.00 to $30.00 in a research note issued on Tuesday. Credit Suisse’s price objective would indicate a potential upside of 90.84% from the company’s current price.
Adamas Pharmaceuticals (NASDAQ:ADMS) traded up 2.36% on Tuesday, hitting $16.49. 40,260 shares of the company’s stock traded hands. Adamas Pharmaceuticals has a one year low of $12.02 and a one year high of $21.63. The stock’s 50-day moving average is $17.01 and its 200-day moving average is $17.48. The company has a market cap of $276.3 million and a price-to-earnings ratio of 6.07.
Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.88 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.81 by $0.07. The company had revenue of $25.15 million for the quarter, compared to the consensus estimate of $18.75 million. Analysts expect that Adamas Pharmaceuticals will post $0.12 EPS for the current fiscal year.
Adamas Pharmaceuticals, Inc is a clinical-stage specialty pharmaceutical company. The Company is developing its lead wholly owned product candidate, ADS-5102, for a complication of Parkinson’s disease known as levodopa induced dyskinesia (NASDAQ:ADMS), and as a treatment for chronic behavioral symptoms associated with traumatic brain injury (TBI).
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.